Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.

Lexeo Therapeutics (NASDAQ:LXEO - Free Report) had its target price reduced by JPMorgan Chase & Co. from $16.00 to $10.00 in a research report report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also recently issued reports on the stock. Royal Bank of Canada decreased their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Chardan Capital decreased their price target on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Finally, HC Wainwright decreased their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of "Buy" and an average target price of $18.50.

Lexeo Therapeutics Trading Down 3.8%

Shares of Lexeo Therapeutics stock traded down $0.11 during trading on Friday, reaching $2.76. 371,002 shares of the company were exchanged, compared to its average volume of 502,297. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $19.50. The business has a 50-day moving average price of $3.03 and a 200-day moving average price of $4.60. The firm has a market capitalization of $91.62 million, a price-to-earnings ratio of -0.87 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Sell-side analysts anticipate that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Lexeo Therapeutics by 19.8% in the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company's stock worth $105,000 after purchasing an additional 4,995 shares during the period. Acadian Asset Management LLC acquired a new stake in Lexeo Therapeutics in the 1st quarter valued at approximately $85,000. Millennium Management LLC raised its position in Lexeo Therapeutics by 654.8% in the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock valued at $3,718,000 after buying an additional 929,538 shares during the last quarter. AQR Capital Management LLC raised its position in Lexeo Therapeutics by 370.0% in the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock valued at $175,000 after buying an additional 39,627 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in Lexeo Therapeutics in the 1st quarter valued at approximately $5,139,000. Institutional investors and hedge funds own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.